Retail investors may miss out on the upside of major IPOs due to limited allocation and preferential treatment for insiders and institutions.
The global copper supply is constrained due to declining ore grades and historical underinvestment, which could lead to significant price volatility.
AI's transformative impact on the core drug development process has not yet been realized, with benefits currently limited to administrative efficiencies.
The standard Chinese biotech model of early-stage development and out-licensing could pose future competitive risks to US and Western pharmaceutical companies.
Opportunities Identified
Impending mega-IPOs of Anthropic, SpaceX, and OpenAI present significant market events and potential investment opportunities.
Surging demand for copper, driven by AI data centers, creates a strong investment case for the commodity and related mining assets, particularly in high-grade regions like the DRC.
Breakthroughs in cancer treatments, such as those for pancreatic cancer presented at ASCO, indicate significant value creation opportunities in the biotech sector.
AI can accelerate the administrative aspects of the FDA drug approval process, potentially speeding up time-to-market for new therapies.